Handling a promising cancer agent that keeps on giving, with BeyondSpring's Ramon Mohanlal

16 November 2016

The promise being shown by plinabulin, not just as a natural compound that could provide multiple potential therapeutic benefits in a variety of cancers but also as an agent that mitigates the side effects and improves the efficacy of an established chemotherapy treatment, is enormous.

Many small companies would therefore love to swap places with the immuno-oncology specialist BeyondSpring, which is developing this asset as its lead drug candidate.

"Our company has a strong focus on innovation but also a strong development strategy combining resources and capabilities in the USA with those in China"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK